We used the NSC algorithm to derive shrunken class means of biomarker protein abundance and gauged the relative quantity of each plasma protein in the SAF and QOM samples to assess the relative resolving power of each biomarker (Fig. 4a) . To validate the antibody array observations, TIMP1 and MMP9 concentrations in SJIA plasma were also determined using enzyme immunometric assay kits from RayBiotech, Inc (Norcross, GA; data not shown). All of the SJIA flare biomarker proteins were found at higher levels in plasma at SJIA flare state. The LDA classification results were used to calculate the percentage of classification that agreed with clinical diagnosis, as shown in a modified 2×2 contingency table (Fig. 4b, left panel) . The six-protein biomarker panel classified the SJIA flare samples with 92% positive agreement and the non-flare samples with 71.4% agreement (Fig. 4c, left panel) 